Association of Serum Vaspin Concentration with Metabolic Disorders in Obese Individuals

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2023 Mar 29

PMID 36979443

Authors

Lukasz Pilarski

Marta Pelczynska

Anna Koperska

Agnieszka Seraszek-Jaros

Monika Szulinska

Pawel Bogdanski

Affiliations

Soon will be listed here.

Abstract

Vaspin, a molecule produced in visceral adipose tissue, seems to participate in the pathogenesis of metabolic disorders. The study aimed to determine the association of vaspin concentration with metabolic disorders in obese individuals. Forty obese patients and twenty normal-weight subjects underwent biochemical (fasting glucose, insulin, lipid profile, interleukin-6, hs-CRP, vaspin concentration), blood pressure, and anthropometric measurements. The HOMA-IR index was calculated. Serum vaspin concentrations in the obese group were significantly higher than in the control group (0.82 ± 0.62 vs. 0.43 ± 0.59; < 0.001). Among the entire population, vaspin concentration was positively correlated with body weight, BMI, WHR, and the percentage and mass of adipose tissue. Positive correlations between vaspin concentration and triglyceride level, insulin concentration, and HOMA-IR value were found. Vaspin concentration was positively correlated with hs-CRP and IL-6 levels. In obese patients, positive correlations between vaspin concentration and the percentage of adipose tissue and hs-CRP level were demonstrated. Logistic regression analysis showed that increased BMI was the biggest factor stimulating vaspin concentrations (OR = 8.5; 95% CI: 1.18-61.35; = 0.0338). An elevated vaspin level may imply its compensatory role against metabolic disorders in obese patients. Thus, vaspin appears to be a useful diagnostic parameter for new therapeutic approaches in obesity-related complications. Nevertheless, due to the small sample size, further studies are needed to confirm our results.

Citing Articles

Association Between Body Mass Index and Glycemic Control in Type 2 Diabetes Mellitus: A Cross-Sectional Study.

Deng L, Jia L, Wu X, Cheng M Diabetes Metab Syndr Obes. 2025; 18:555-563.

PMID: 40007519 PMC: 11853989. DOI: 10.2147/DMSO.S508365.

Zhang Q, Zhao Y, Li L, Fan Q, Huang B, Du H J Inflamm Res. 2025; 18:1207-1233.

PMID: 39886385 PMC: 11780177. DOI: 10.2147/JIR.S499835.

Evaluation of Selected Pro- and Anti-Inflammatory Adipokines in Colostrum from Mothers with Gestational Diabetes Mellitus.

Lis-Kuberka J, Berghausen-Mazur M, Orczyk-Pawilowicz M Int J Mol Sci. 2025; 26(1.

PMID: 39795898 PMC: 11719563. DOI: 10.3390/ijms26010040.

The effect of hydrophilic statins on adiponectin, leptin, visfatin, and vaspin levels in streptozocin-induced diabetic rats.

Kaya H, Demirtas B Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39382680 DOI: 10.1007/s00210-024-03517-6.

Adipose Tissue, Non-Communicable Diseases, and Physical Exercise: An Imperfect Triangle.

Monsalve F, Delgado-Lopez F, Fernandez-Tapia B, Gonzalez D Int J Mol Sci. 2023; 24(24).

PMID: 38138997 PMC: 10743187. DOI: 10.3390/ijms242417168.

References

Tarabeih N, Kalinkovich A, Shalata A, Livshits G . Circulating Levels of Visceral Adipose Tissue-Derived Serine Protease Inhibitor (Vaspin) Appear as a Marker of Musculoskeletal Pain Disability. Diagnostics (Basel). 2020; 10(10). PMC: 7599595. DOI: 10.3390/diagnostics10100797. View

Sato K, Shirai R, Yamaguchi M, Yamashita T, Shibata K, Okano T . Anti-Atherogenic Effects of Vaspin on Human Aortic Smooth Muscle Cell/Macrophage Responses and Hyperlipidemic Mouse Plaque Phenotype. Int J Mol Sci. 2018; 19(6). PMC: 6032338. DOI: 10.3390/ijms19061732. View

Moradi S, Mirzaei K, Abdurahman A, Keshavarz S, Hossein-Nezhad A . Mediatory effect of circulating vaspin on resting metabolic rate in obese individuals. Eur J Nutr. 2015; 55(3):1297-305. DOI: 10.1007/s00394-015-0948-4. View

Suleymanoglu S, Tascilar E, Pirgon O, Tapan S, Meral C, Abaci A . Vaspin and its correlation with insulin sensitivity indices in obese children. Diabetes Res Clin Pract. 2009; 84(3):325-8. DOI: 10.1016/j.diabres.2009.03.008. View

Jung C, Lee M, Kang Y, La Lee Y, Yoon H, Kang S . Vaspin inhibits cytokine-induced nuclear factor-kappa B activation and adhesion molecule expression via AMP-activated protein kinase activation in vascular endothelial cells. Cardiovasc Diabetol. 2014; 13:41. PMC: 3925442. DOI: 10.1186/1475-2840-13-41. View

Heiker J, Kloting N, Kovacs P, Kuettner E, Strater N, Schultz S . Vaspin inhibits kallikrein 7 by serpin mechanism. Cell Mol Life Sci. 2013; 70(14):2569-83. PMC: 3689916. DOI: 10.1007/s00018-013-1258-8. View

Taheri E, Hosseini S, Qorbani M, Mirmiran P . Association of adipocytokines with lipid and glycemic profiles in women with normal weight obesity. BMC Endocr Disord. 2020; 20(1):171. PMC: 7670687. DOI: 10.1186/s12902-020-00648-8. View

Zieger K, Weiner J, Krause K, Schwarz M, Kohn M, Stumvoll M . Vaspin suppresses cytokine-induced inflammation in 3T3-L1 adipocytes via inhibition of NFκB pathway. Mol Cell Endocrinol. 2017; 460:181-188. DOI: 10.1016/j.mce.2017.07.022. View

Feng R, Li Y, Wang C, Luo C, Liu L, Chuo F . Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: a meta-analysis. Diabetes Res Clin Pract. 2014; 106(1):88-94. DOI: 10.1016/j.diabres.2014.07.026. View

10.

Nakatsuka A, Wada J, Iseda I, Teshigawara S, Higashio K, Murakami K . Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex. Diabetes. 2012; 61(11):2823-32. PMC: 3478540. DOI: 10.2337/db12-0232. View

11.

Pasco J, Holloway K, Dobbins A, Kotowicz M, Williams L, Brennan S . Body mass index and measures of body fat for defining obesity and underweight: a cross-sectional, population-based study. BMC Obes. 2015; 1:9. PMC: 4511447. DOI: 10.1186/2052-9538-1-9. View

12.

Shin J, Toyoda S, Nishitani S, Fukuhara A, Kita S, Otsuki M . Possible Involvement of Adipose Tissue in Patients With Older Age, Obesity, and Diabetes With SARS-CoV-2 Infection (COVID-19) via GRP78 (BIP/HSPA5): Significance of Hyperinsulinemia Management in COVID-19. Diabetes. 2021; 70(12):2745-2755. PMC: 8660985. DOI: 10.2337/db20-1094. View

13.

Recinella L, Orlando G, Ferrante C, Chiavaroli A, Brunetti L, Leone S . Adipokines: New Potential Therapeutic Target for Obesity and Metabolic, Rheumatic, and Cardiovascular Diseases. Front Physiol. 2020; 11:578966. PMC: 7662468. DOI: 10.3389/fphys.2020.578966. View

14.

Yang L, Chen S, Yuan G, Wang D, Chen J . Changes and clinical significance of serum vaspin levels in patients with type 2 diabetes. Genet Mol Res. 2015; 14(3):11356-61. DOI: 10.4238/2015.September.25.2. View

15.

Kloting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schon M . Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun. 2005; 339(1):430-6. DOI: 10.1016/j.bbrc.2005.11.039. View

16.

Kloting N, Kovacs P, Kern M, Heiker J, Fasshauer M, Schon M . Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia. 2011; 54(7):1819-23. DOI: 10.1007/s00125-011-2137-1. View

17.

Mlyczynska E, Kiezun M, Kurowska P, Dawid M, Pich K, Respekta N . New Aspects of Corpus Luteum Regulation in Physiological and Pathological Conditions: Involvement of Adipokines and Neuropeptides. Cells. 2022; 11(6). PMC: 8946127. DOI: 10.3390/cells11060957. View

18.

Aliasghari F, Izadi A, Jabbari M, Imani B, Pourghassem Gargari B, Asjodi F . Are Vaspin and Omentin-1 Related to Insulin Resistance, Blood Pressure and Inflammation in NAFLD Patients?. J Med Biochem. 2018; 37(4):470-475. PMC: 6298482. DOI: 10.2478/jomb-2018-0006. View

19.

Brunetti L, Di Nisio C, Recinella L, Chiavaroli A, Leone S, Ferrante C . Effects of vaspin, chemerin and omentin-1 on feeding behavior and hypothalamic peptide gene expression in the rat. Peptides. 2011; 32(9):1866-71. DOI: 10.1016/j.peptides.2011.08.003. View

20.

Auguet T, Quintero Y, Riesco D, Morancho B, Terra X, Crescenti A . New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet. 2011; 12:60. PMC: 3107780. DOI: 10.1186/1471-2350-12-60. View